Celldex CFO Martin Bates Buys 93,000 Shares
Martin Bates, CFO of Celldex, acquired 93,000 shares, signaling confidence in the company's future.
Key Points
- Martin Bates, the CFO of Celldex Therapeutics, purchased 93,000 shares on June 25, 2026.
- Celldex Therapeutics has a market cap of $2.77 billion, with shares trading at $35.26 on Tuesday.
- Analysts from firms like HC Wainwright & Co. and UBS maintain a 'buy' rating on Celldex, with price targets up to $68.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Celldex Therapeutics, Inc.'s CFO, Martin Samuel Bates, made a substantial purchase of 93,000 shares on June 25, 2026. This insider activity reflects a significant show of confidence from the company's senior financial officer.
Insider Buying and Selling at Celldex Therapeutics, Inc.
On June 25, 2026, several insiders at Celldex Therapeutics, including Martin Samuel Bates, the Senior Vice President and CFO, bought shares in the company. Bates acquired 93,000 shares, while other executives such as Ronald Pepin, Denice Torres, and Neil Garry Arthur also made purchases. These transactions were not part of any pre-arranged trading plans.
Celldex Therapeutics, Inc. Stock Down 4.3%
Shares of NasdaqCM:CLDX traded at $35.26 on Tuesday. Celldex Therapeutics has a market cap of approximately $2.77 billion. The stock has a 52-week range between $19.52 and $35.79, with a 50-day moving average of $32.10 and a 200-day moving average of $28.27. The company, which operates in the biotechnology sector, shows a current ratio of 8.92 and a quick ratio of 8.78, indicating strong liquidity.
$CLDX stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts are optimistic about Celldex's future. On June 15, 2026, HC Wainwright & Co. reiterated a 'buy' rating with a target price of $42. UBS maintained its 'buy' rating with a $45 target on June 10. Wells Fargo and Barclays also maintain 'buy' ratings, with targets of $54 and $48, respectively. The analyst consensus is a 'strong buy' with a mean target price of $57.53, reflecting positive sentiment about the company's potential.
About Celldex Therapeutics
Celldex Therapeutics, Inc. is a biopharmaceutical company based in Hampton, New Jersey. It focuses on developing therapeutic antibodies for severe inflammatory, allergic, autoimmune, and other diseases. The company's pipeline includes monoclonal and bispecific antibodies targeting mast cell mediated diseases. Led by CEO Anthony S. Marucci, Celldex employs 198 people and continues to advance its clinical programs.
Bottom Line
The recent insider buying by Celldex Therapeutics' CFO, Martin Bates, is a notable event that investors often watch for signs of executive confidence. While 13F filings and insider transactions provide a historical snapshot, they do not necessarily indicate current positions or future performance. Analyst ratings remain positive, suggesting a strong outlook for the company.
Get Celldex Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CLDX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.